---
document_datetime: 2024-10-23 11:11:07
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/edurant-epar-all-authorised-presentations_en.pdf
document_name: edurant-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6738258
conversion_datetime: 2025-12-20 17:17:59.053874
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number                  | (Invented) name   | Strength     | Pharmaceutical Form                   | Route of Administration   | Immediate Packaging                                               | Pack size                             |
|---------------------------------|-------------------|--------------|---------------------------------------|---------------------------|-------------------------------------------------------------------|---------------------------------------|
| EU/1/11/736/001 EU/1/11/736/002 | Edurant Edurant   | 25 mg 2.5 mg | Film-coated tablet Dispersible tablet | Oral use Oral use         | bottle (HDPE) blister (PA/alu/PVC/PE/desicc ant-paper/PET/alu/PE) | 30 tablets 90 x 1 tablets (unit dose) |